share_log

Stifel Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $45

Benzinga ·  Mar 7, 2023 05:21

Stifel analyst Annabel Samimy initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment